Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Levalbuterol/Levosalbutamol
DRUG
2 trials
Sponsors
Sanofi
Conditions
Asthma
Phase 3
Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)
Completed
NCT02414854
Sanofi
Asthma
Start: 2015-04-27
End: 2017-11-23
Updated: 2018-10-23
Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma
Completed
NCT02528214
Sanofi
Asthma
Start: 2015-10-15
End: 2017-11-13
Updated: 2019-10-01
Related Papers
Data-driven trial design: use of target trial emulation to evaluate eligibility criteria in asthma and COPD
Frontiers in Medicine
2026-06-23
Transient early blood eosinophil increases do not affect dupilumab's long-term efficacy in patients with moderate-to-severe asthma.
2025-11-14
Impact of asthma age of onset or duration on efficacy of dupilumab in moderate-to-severe type 2 asthma.
2025-08-06
Dupilumab efficacy in patients with type 2 asthma and early Feno level reductions.
2025-04-15
Effect of Tezepelumab on Sino-Nasal Outcome Test (SNOT)-22 Domain and Symptom-Specific Scores in Patients with Severe, Uncontrolled Asthma and a History of Chronic Rhinosinusitis with Nasal Polyps.
2024-11-08
5 citations
Dupilumab Induces Long-Term On-Treatment Clinical Remission in Patients With Type 2 Asthma.
2024-10-16
17 citations
Cost-effectiveness analysis of dupilumab among patients with uncontrolled severe asthma using LIBERTY ASTHMA QUEST Korean data.
2024-08-26
5 citations
Long-Term Efficacy of Dupilumab in Moderate-to-Severe Asthma Phenotyped by Blood Eosinophils and Exhaled Nitric Oxide
CHEST Pulmonary
2024-07-04
Long-term Safety and Efficacy of Dupilumab in Patients With Uncontrolled, Moderate-to-Severe Asthma Recruited From Korean Centers: A Subgroup Analysis of the Phase 3 LIBERTY ASTHMA TRAVERSE Trial.
2024-07-01
2 citations
Dupilumab Reduces Exacerbations Independent of Changes in Biomarkers in Moderate-to-Severe Asthma.
2024-03-29
7 citations
Impact of Exacerbation History on Dupilumab Efficacy in Children with Uncontrolled Moderate-to-Severe Asthma: LIBERTY ASTHMA VOYAGE Study.
2024-03-05
1 citations
Association Of Baseline Lung Function And Likelihood Of Oral Corticosteroid Reduction In Patients With OCS-Dependent Severe Asthma
Pneumologie
2024-03-01
Fractional exhaled nitric oxide as a biomarker in patients with uncontrolled asthma
Pneumologie
2024-03-01
Impact of dupilumab across seasons in patients with type 2, uncontrolled, moderate-to-severe asthma
Annals of Allergy Asthma & Immunology
2023-11-26
6 citations
S118 Dupilumab efficacy is not affected by prior asthma exacerbation status in LIBERTY ASTHMA TRAVERSE open-label extension study
2023-11-01
P124 Stability of fractional exhaled nitric oxide levels as a biomarker in patients with uncontrolled asthma
2023-11-01
Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils
Journal of Immunology Research
2023-10-19
13 citations
Efficacy of dupilumab in patients with uncontrolled, moderate‐to‐severe asthma with fungal sensitization
Clinical & Experimental Allergy
2023-09-26
4 citations
Fractional exhaled nitric oxide as a biomarker in patients with uncontrolled asthma
2023-09-09
Long-Term Dupilumab Efficacy in Patients with Type 2 Asthma by Age of Onset: Liberty asthma traverse
2023-09-09
85 more papers not shown